- 全部删除
您的购物车当前为空
Vodobatinib (K-0706) 是第三代具有口服活性的Bcr-Abl1酪氨酸激酶抑制剂,IC50=7 nM,对大多数 BCR-ABL1 点突变体具有活性,但对 BCR-ABL1T315I 无活性。它可用于研究慢性粒细胞白血病 (CML)。


为众多的药物研发团队赋能,
让新药发现更简单!
Vodobatinib (K-0706) 是第三代具有口服活性的Bcr-Abl1酪氨酸激酶抑制剂,IC50=7 nM,对大多数 BCR-ABL1 点突变体具有活性,但对 BCR-ABL1T315I 无活性。它可用于研究慢性粒细胞白血病 (CML)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 315 | In stock | |
| 5 mg | ¥ 738 | In stock | |
| 10 mg | ¥ 1,230 | In stock | |
| 25 mg | ¥ 2,320 | In stock | |
| 50 mg | ¥ 3,730 | In stock | |
| 100 mg | ¥ 5,320 | In stock | |
| 500 mg | ¥ 10,800 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 815 | In stock |
Vodobatinib 相关产品
| 产品描述 | Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity. |
| 靶点活性 | BCR-ABL1:7 nM (IC50) |
| 别名 | K-0706 |
| 分子量 | 453.92 |
| 分子式 | C27H20ClN3O2 |
| CAS No. | 1388803-90-4 |
| Smiles | Cc1ccc(cc1C#Cc1cnc2ccccc2c1)C(=O)NNC(=O)c1c(C)cccc1Cl |
| 密度 | 1.35 g/cm3 (Predicted) |
| 存储 | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 25 mg/mL (55.08 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容